FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra® (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra® was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra®.

In the clinical trials results were evaluated based on progression free survival (PFS), which is the length of time a patient lives with a disease but it does not worsen. Arzerra® in combination with chlorambucil showed an average PFS of 22.4 months as compared to an average PFS of 13.1 months in patients receiving chlorambucil alone.

According to the American Cancer Society, CLL accounts for approximately one-third of new leukemia cases in adults. The average age at diagnosis is 72 years and is considered extremely rare in patients under the age of 40.

The most common adverse reactions to Arzerra® were related to the administration of the drug via infusion and were considered to be Grade 2 or lower. The most common adverse reactions unrelated to the infusion process were neutropenia, asthenia, headache, leukopenia, herpes simplex, lower respiratory infection, arthralagia and upper abdominal pain.  

Arzerra® is manufactured by GLAXO GROUP LIMITED and distributed by Glaxo Smith Kline.

Source:

Diplomat Pharmacy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty